SecBot SecBot
SECBOTREPLAY Home › Report › NVO

NVO · The District of New Jersey partially denied Novo Nordisk's motion to…

NOVO NORDISK A S · COURT-RULING filed Jul 27, 2026 at 20:00 ET

At the news

BEARISHIMPACT 5/10

COURT-RULING filed Jul 27, 2026 at 20:00 ET

The District of New Jersey partially denied Novo Nordisk's motion to dismiss a securities class action, allowing claims to proceed that Novo misled investors by not disclosing a flexible dosing protocol in its CagriSema REDEFINE 1 trial when making statements about the drug's tolerability. The ruling keeps Novo and its EVP of Development Martin Lange as defendants on three specific tolerability-related statements, while dismissing most other claims including those against former CEO Jørgensen. The litigation overhang persists, but the core adverse information has been public since December 2024 when the stock fell 17.8%.

  • Novo's motion to dismiss was granted in part and denied in part on July 28, 2026
  • Three statements by EVP Martin Lange about CagriSema's tolerability survive under Section 10(b)
  • Claims about fixed-dose structure, weight loss predictions, and future trial slides were dismissed
  • CEO Jørgensen dismissed from Section 10(b) claim but remains on Section 20(a) control person claim

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access